Cargando…
Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics
The 2019 novel coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has occurred in China and around the world. SARS-CoV-2-infected patients with severe pneumonia rapidly develop acute respiratory distress syndrome (ARDS) and die of multiple org...
Autores principales: | Qin, Hua, Zhao, Andong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Higher Education Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7282699/ https://www.ncbi.nlm.nih.gov/pubmed/32519302 http://dx.doi.org/10.1007/s13238-020-00738-2 |
Ejemplares similares
-
Current status and prospects of basic research and clinical application of mesenchymal stem cells in acute respiratory distress syndrome
por: Liang, Tian-Yu, et al.
Publicado: (2023) -
Mesenchymal stem cells - a promising therapy for Acute Respiratory Distress Syndrome
por: Hayes, Mairead, et al.
Publicado: (2012) -
Genetically modified mesenchymal stem cell therapy for acute respiratory distress syndrome
por: Han, Jibin, et al.
Publicado: (2019) -
Recent insights: mesenchymal stromal/stem cell therapy for acute respiratory distress syndrome
por: Horie, Shahd, et al.
Publicado: (2016) -
Strategies to Enhance Mesenchymal Stem Cell-Based Therapies for Acute Respiratory Distress Syndrome
por: Han, Jibin, et al.
Publicado: (2019)